Pharmacovigilance of Radiopharmaceuticals: Challenges and Opportunities.
作者信息
Martins Sara, Jesus Ângelo, Suárez Ana Martín-
机构信息
LAQV/REQUIMTE, Escola Superior de Saúde, Instituto Politécnico do Porto, Porto, Portugal.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
出版信息
J Pharm Technol. 2024 Oct;40(5):257-259. doi: 10.1177/87551225241266172. Epub 2024 Jul 27.
Abstract
摘要
相似文献
1
Pharmacovigilance of Radiopharmaceuticals: Challenges and Opportunities.放射性药物的药物警戒：挑战与机遇
J Pharm Technol. 2024 Oct;40(5):257-259. doi: 10.1177/87551225241266172. Epub 2024 Jul 27.
2
Assessment of pharmacovigilance knowledge and ADR reporting skills in undergraduate medical students using the OSPA model.使用OSPA模型评估本科医学生的药物警戒知识和药品不良反应报告技能。
Dialogues Health. 2025 Jul 3;7:100227. doi: 10.1016/j.dialog.2025.100227. eCollection 2025 Dec.
3
Adverse Reactions to Radiopharmaceuticals: A Survey Based on Clinical Cases Using Criteria of Systematic Review.放射性药物的不良反应：基于临床病例并采用系统评价标准的一项调查
Ther Innov Regul Sci. 2018 Jan;52(1):109-113. doi: 10.1177/2168479017716717. Epub 2017 Jun 30.
4
Assessment of knowledge and perceptions of pharmacy students toward pharmacovigilance activities, and their predictors: a cross-sectional study in Palestine.巴勒斯坦药学专业学生对药物警戒活动的知识与认知评估及其预测因素：一项横断面研究
BMC Med Educ. 2025 Jul 17;25(1):1067. doi: 10.1186/s12909-025-07575-z.
5
Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.建立功能完善且可持续的药物警戒系统：对高、中、低收入国家药物警戒发展情况的分析
Ther Adv Drug Saf. 2025 Jun 10;16:20420986251342941. doi: 10.1177/20420986251342941. eCollection 2025.
6
Adverse reactions mediated by Tc-tetrofosmin: Literature review and analysis of post-marketing reports.锝-替曲膦介导的不良反应：文献综述及上市后报告分析
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2025 Jun 9:500166. doi: 10.1016/j.remnie.2025.500166.
7
Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database.法国放射性药物的不良反应：国家药物警戒数据库分析
Ann Pharmacother. 2015 Jan;49(1):39-47. doi: 10.1177/1060028014558153. Epub 2014 Nov 3.
8
Training and education in pharmacovigilance: The experience from the Pharmacovigilance Programme of India.药物警戒方面的培训与教育：来自印度药物警戒计划的经验。
Indian J Pharmacol. 2024 Sep 1;56(5):348-357. doi: 10.4103/ijp.ijp_638_22. Epub 2024 Dec 16.
9
Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation.低收入和中等收入国家的药物警戒流程：从数据收集转向数据分析与解读
Ther Adv Drug Saf. 2025 Jun 11;16:20420986241300006. doi: 10.1177/20420986241300006. eCollection 2025.
10
An observational pilot study of an active surveillance tool to enhance pharmacovigilance in Brazil.一项关于在巴西增强药物警戒的主动监测工具的观察性试点研究。
Malar J. 2025 Mar 3;24(1):71. doi: 10.1186/s12936-025-05295-9.
本文引用的文献
1
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.放射性药物：探索精准医学与治疗创新的前沿。
Eur J Med Res. 2024 Jan 5;29(1):26. doi: 10.1186/s40001-023-01627-0.
2
Underreporting of Adverse Drug Events: a Look into the Extent, Causes, and Potential Solutions.药品不良事件报告不足：对其程度、原因及潜在解决办法的探究
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):351-354. doi: 10.1080/14740338.2023.2224558. Epub 2023 Jun 13.
3
Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update.与医疗保健专业人员报告药物不良反应不足相关的因素：系统评价更新。
Drug Saf. 2023 Jul;46(7):625-636. doi: 10.1007/s40264-023-01302-7. Epub 2023 Jun 6.
4
Pharmacovigilance: reporting requirements throughout a product's lifecycle.药物警戒：产品全生命周期的报告要求
Ther Adv Drug Saf. 2022 Sep 27;13:20420986221125006. doi: 10.1177/20420986221125006. eCollection 2022.
5
Review of Adverse Reactions Associated with the Use of Common Diagnostic Radiopharmaceuticals.与常用诊断性放射性药物使用相关的不良反应综述
Indian J Nucl Med. 2021 Apr-Jun;36(2):163-167. doi: 10.4103/ijnm.ijnm_219_20. Epub 2021 Jun 21.
6
Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.放射性药物小规模制备现行良好放射性药物生产规范（cGRPP）指南。
EJNMMI Radiopharm Chem. 2021 Feb 12;6(1):8. doi: 10.1186/s41181-021-00123-2.
7
Adverse reactions to radiopharmaceuticals: liver radiopharmaceuticals.放射性药物不良反应：肝脏放射性药物。
Nucl Med Commun. 2021 Apr 1;42(4):352-359. doi: 10.1097/MNM.0000000000001355.
8
Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients.患者报告的放射性药物不良反应：1002 例患者的前瞻性研究。
Drug Saf. 2021 Feb;44(2):211-222. doi: 10.1007/s40264-020-01006-2. Epub 2020 Oct 22.
9
Full report on a survey of adverse reactions to radiopharmaceuticals from 1975 to 2017 in Japan.日本 1975 年至 2017 年放射性药物不良反应调查的全面报告。
Ann Nucl Med. 2020 Apr;34(4):299-304. doi: 10.1007/s12149-020-01439-w. Epub 2020 Jan 27.
10
Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review.诊断用放射性药物的不良反应：系统评价。
Semin Nucl Med. 2019 Sep;49(5):382-410. doi: 10.1053/j.semnuclmed.2019.06.006.
Zotero 插件